Immunic, Inc. (IMUX): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMUX Stock Price Chart Interactive Chart >
IMUX Price/Volume Stats
| Current price | $2.24 | 52-week high | $14.50 |
| Prev. close | $2.07 | 52-week low | $1.11 |
| Day low | $2.06 | Volume | 1,869,776 |
| Day high | $2.30 | Avg. volume | 1,104,017 |
| 50-day MA | $1.42 | Dividend yield | N/A |
| 200-day MA | $3.92 | Market Cap | 99.36M |
Immunic, Inc. (IMUX) Company Bio
Immunic Inc. (formerly Vital Therapies) is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The company was founded in 2003 and is based in San Diego, California.
Latest IMUX News From Around the Web
Below are the latest news stories about IMMUNIC INC that investors may wish to consider to help them evaluate IMUX as an investment opportunity.
Immunic to Participate in Scientific and Investor Conferences in FebruaryImmunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in February: |
Quite a few insiders invested in Immunic, Inc. (NASDAQ:IMUX) last year which is positive news for shareholdersWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Immunic: Revisiting A 'Lottery Ticket'
When we last looked in on a small-cap biotech company called Immunic, Inc. (IMUX), the country was coming off the first series of Covid-related lockdowns. We concluded that article around Immunic by calling it a 'lottery ticket' that was only worthy of ... |
Immunic (IMUX) Receives a Buy from WedbushE ratio of -0.48. |
Immunic Soars on Promising Multiple Sclerosis DataShares of clinical-stage biopharmaceutical company Immunic (NASDAQ:IMUX) are soaring higher today after the company announced promising data from a Phase 2 study evaluating vidofludimus calcium (IMU-838) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Long-term treatment with Immunic’s lead candidate was associated with a low rate of disability worsening over time. Further, the results compare favorably with available trial data for current MS medications. Despite today’s price gains, Immunic shares are still down ~87% year-to-date. Moreover, short interest in the stock remains elevated at about 23.6% at present. |
IMUX Price Returns
| 1-mo | 76.38% |
| 3-mo | 26.55% |
| 6-mo | -36.72% |
| 1-year | -79.58% |
| 3-year | -74.16% |
| 5-year | -99.09% |
| YTD | 60.00% |
| 2022 | -85.37% |
| 2021 | -37.41% |
| 2020 | 57.63% |
| 2019 | 27.63% |
| 2018 | -96.81% |
Loading social stream, please wait...